MYSEC-mPM / MYSEC-kmPM (molecular/karyotype-augmented MYSEC-PM)

Current understanding

MYSEC-mPM adds ASXL1 and UTS (U2AF1, TP53, SRSF2) mutation signatures to the clinical MYSEC-PM, and MYSEC-kmPM further incorporates complex/monosomal karyotype; both refinements significantly improve overall-survival prediction in post-PV and post-ET myelofibrosis versus MYSEC-PM alone. Evidence to date is observational from a large MYSEC-cohort NGS analysis. Practically, these scores can up- or down-stage secondary MF patients around transplant referral thresholds that MYSEC-PM would otherwise miscall.

Evidence log

• 2026-07-01 — Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis.: cross-connection with mysec-pm: MYSEC-mPM/kmPM are molecular- and karyotype-augmented extensions of MYSEC-PM for secondary MF risk stratification. (novelty: 3)

Open questions

Related